Biden's NIH nominee languishes in Congress; how the new weight loss drugs are revolutionizing scientific understanding

Taking stock of the drug industry, from the lab to the medicine chest

July 10, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jeff Chiu/AP Biden's NIH nominee is languishing in Congress — alarming public health advocates Public health advocates worry the feud between Biden and Bernie Sanders could squeeze out an otherwise uncontroversial pick to lead the NIH. By Sarah Owermohle STAT+ | Blue Cross Blue Shield insurers keep winning from Affordable Care Act's risk program More than two dozen BCBS insurers are projected to collect more than $4.7 billion from competing insurers on the ACA marketplaces. By Bob Herman STAT+ | The new weight loss drugs are revolutionizing our understanding of desire. Food cravings could be just the beginning Recent research raises a striking question: If new weight loss drugs erase food cravings, what other harmful desires might they free us from? By Megan Molteni Courtesy Richard Huckabee Why nearly half of Americans with Parkinson's don't see a neurologist A new study drives home the extent to which many Parkinson's patients struggle to access care for their physical and mental health. By Simar Bajaj

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser